Synopsis:
Cohance Lifesciences Ltd’s share declined over 5% after its promoter Jusmiral Holdings Ltd is likely to sell 5.1% stake in the company.
A leading global CDMO (Contract Development and Manufacturing Organization) is in the spotlight today after its promoter is likely to sell 5.1 percent stake in the company through a block deal.
With a market capitalization of Rs. 35,054.63 crore,Cohance Lifesciences Ltd is trading at Rs. 915.90, down by 5.26 percent from its previous close of Rs. 966.35 per equity share. The shares touched an intraday low of Rs. 906 in today’s trading session.
What’s the News?
As per the sources, Promoter Jusmiral Holdings Ltd is likely to divest up to 5.1% stake in the company through block deals, with the transaction valued at ₹1,756 crore and a floor price set at ₹900 per share. As of June 2025, Jusmiral Holdings Ltd holds a 33.08 percent stake in the company.
Also Read: Video: Son Heung-min Scores First MLS Hat Trick in LAFC’s 4-1 Win vs Real Salt Lake
About the company
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is a Hyderabad based company founded in 1989 and now a subsidiary of Berhyanda Limited. It operates in India, the US, Europe, and globally, providing contract research, development, and manufacturing services for NCE-based intermediates, APIs, specialty chemicals, and formulated drugs.
Its portfolio includes small molecule APIs, advanced intermediates, antibody drug conjugates, oligonucleotide building blocks, pellets, finished dosage forms, and agrochemicals, catering to pharmaceutical, biotech, and chemical companies.
It is trading at a price-to-earnings (P/E) ratio of 99.6x, which is higher than the industry average of 33.8x. A return on equity (ROE) of about 12.7 percent and a return on capital employed (ROCE) of about 14.9 percent demonstrate the company’s financial position.
In Q1FY26, the company reported revenue of ₹549 crore, up 12% YoY from ₹488 crore but down 35% QoQ from ₹840 crore. Net profit stood at ₹46 crore, declining 39% YoY from ₹75 crore and 61% QoQ from ₹117 crore, indicating revenue growth on a yearly basis but sharp sequential and annual profit pressure.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
